These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20163903)

  • 1. Co-operation between patient organisations and the drug industry in Finland.
    Hemminki E; Toiviainen HK; Vuorenkoski L
    Soc Sci Med; 2010 Apr; 70(8):1171-5. PubMed ID: 20163903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of the pharmaceutical industry in patient organisations].
    Vermeulen M; Bouma J
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2432-4. PubMed ID: 18064861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.
    Ball DE; Tisocki K; Herxheimer A
    BMC Public Health; 2006 Aug; 6():201. PubMed ID: 16887025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In diabetes fight, raising cash and keeping trust.
    Santora M
    N Y Times Web; 2006 Nov; ():A1, B4. PubMed ID: 17167875
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical education and communication companies: an updated in-depth profile.
    Golden GA; Parochka JN; Overstreet KM
    J Contin Educ Health Prof; 2002; 22(1):55-62. PubMed ID: 12004641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finnish physicians show little support for consumer advertising of prescription drugs.
    Toivianen H; Vuorenkoski L; Hemminki E
    N Z Med J; 2004 Jun; 117(1195):U907. PubMed ID: 15282621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
    Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K
    Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conflict of interest or productive collaboration? The pharma: academic relationship and its implications for headache medicine.
    Finkel AG
    Headache; 2006; 46(7):1181-5. PubMed ID: 16866722
    [No Abstract]   [Full Text] [Related]  

  • 9. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
    Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
    PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposing drug industry funding of UK patient organisations.
    Ozieranski P; Rickard E; Mulinari S
    BMJ; 2019 May; 365():l1806. PubMed ID: 31122928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of a mandatory guideline that prohibit hospital doctors from accepting any form of benefits in any form from the pharmaceutical industry].
    Gundermann C; Meier-Hellmann A; Bauer M; Hartmann M
    Dtsch Med Wochenschr; 2010 May; 135(3):67-70. PubMed ID: 20077378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A proposal for the prevention of ethical problems related to drug promotion: a national network for drug information].
    Civaner M
    Turk Psikiyatri Derg; 2008; 19(3):310-7. PubMed ID: 18791884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
    Brand R
    State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
    [No Abstract]   [Full Text] [Related]  

  • 14. [Advantages of cooperation with self-help organisations for out-patient physicians].
    Litschel A; Borgetto B
    Z Arztl Fortbild Qualitatssich; 2005; 99(10):617-21. PubMed ID: 16433263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Physicians and drug industry: attitudes and practice].
    Aasland OG; Førde R
    Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2603-6. PubMed ID: 15534631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Too friendly? Teaching hospitals revisit ties to pharmaceutical firms.
    Romano M
    Mod Healthc; 2003 Jul; 33(28):17. PubMed ID: 12884711
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety management in multiemployer worksites in the manufacturing industry: opinions on co-operation and problems encountered.
    Nenonen S; Vasara J
    Int J Occup Saf Ergon; 2013; 19(2):167-83. PubMed ID: 23759189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed guidelines for housestaff interaction with pharmaceutical companies.
    Forrest DM; Ruedy J
    Ann R Coll Physicians Surg Can; 1993 Oct; 26(5):291-3. PubMed ID: 15362243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.